bluebird bio Statistics
Share Statistics
bluebird bio has 9.72M shares outstanding. The number of shares has increased by 0.61% in one year.
| Shares Outstanding | 9.72M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.61% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 192.73M |
| Failed to Deliver (FTD) Shares | 41.55K |
| FTD / Avg. Volume | 10.8% |
Short Selling Information
The latest short interest is 47.71M, so 24.53% of the outstanding shares have been sold short.
| Short Interest | 47.71M |
| Short % of Shares Out | 24.53% |
| Short % of Float | 24.75% |
| Short Ratio (days to cover) | 9.53 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is -0.6.
| PE Ratio | -0.72 |
| Forward PE | -0.6 |
| PS Ratio | 5.14 |
| Forward PS | 0.2 |
| PB Ratio | 0.78 |
| P/FCF Ratio | -0.62 |
| PEG Ratio | n/a |
Enterprise Valuation
bluebird bio Inc. has an Enterprise Value (EV) of 712.19M.
| EV / Earnings | -3.36 |
| EV / Sales | 24.14 |
| EV / EBITDA | -4.26 |
| EV / EBIT | -2.92 |
| EV / FCF | -2.92 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.
| Current Ratio | 1.41 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -14.94 |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on capital (ROIC) is -46.51%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -46.51% |
| Revenue Per Employee | 78.66K |
| Profits Per Employee | -565.10K |
| Employee Count | 375 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | -126.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 94.5% in the last 52 weeks. The beta is 0.8, so bluebird bio 's price volatility has been higher than the market average.
| Beta | 0.8 |
| 52-Week Price Change | 94.5% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 46.76 |
| Average Volume (20 Days) | 384.80K |
Income Statement
In the last 12 months, bluebird bio had revenue of $29.50M and earned -$211.91M in profits. Earnings per share was $-1.93.
| Revenue | 29.50M |
| Gross Profit | -4.03M |
| Operating Income | -244.26M |
| Net Income | -211.91M |
| EBITDA | -167.16M |
| EBIT | -244.26M |
| Earnings Per Share (EPS) | -1.93 |
Balance Sheet
The company has $221.75M in cash and $330.33M in debt, giving a net cash position of -$108.57M.
| Cash & Cash Equivalents | 221.75M |
| Total Debt | 330.33M |
| Net Cash | -108.57M |
| Retained Earnings | -4.26B |
| Total Assets | 465.06M |
| Working Capital | -145.22M |
Cash Flow
In the last 12 months, operating cash flow was -$235.05M and capital expenditures -$9.06M, giving a free cash flow of -$244.10M.
| Operating Cash Flow | -235.05M |
| Capital Expenditures | -9.06M |
| Free Cash Flow | -244.10M |
| FCF Per Share | -2.22 |
Margins
Gross margin is -13.66%, with operating and profit margins of -828.09% and -718.42%.
| Gross Margin | -13.66% |
| Operating Margin | -828.09% |
| Pretax Margin | -718.85% |
| Profit Margin | -718.42% |
| EBITDA Margin | -566.71% |
| EBIT Margin | -828.09% |
| FCF Margin | -827.55% |
Dividends & Yields
BLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -30.35% |
| FCF Yield | -395.01% |
Analyst Forecast
The average price target for BLUE is $36.8, which is 478.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $36.8 |
| Price Target Difference | 478.6% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Dec 13, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Dec 13, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -15.05 |
| Piotroski F-Score | 2 |